Essentiale
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (March 2010) |
Essentiale is a preparation of essential phospholipids. Essentiale normalizes the metabolism of lipids and proteins, improves the detoxification function of the liver, restores the cellular structure of the liver and retards the producing of conjunctive tissue. Essentiale medications are indicated for the treatment of fatty degeneration of the liver, hepatitis (including toxic hepatitis, liver damage caused by medicines or alcohol abuse), cirrhosis of the liver, disturbances in liver function associated with different illnesses.
Contents
Pharmaceutical action
Phospholipids are essential structural components of all cellular membranes. Essential phospholipids (substance EPL) - are the complex substances of natural origin (ethers of cholinephosphoric acid (phosphatidylcholine) and unsaturated fatty acids (linoleic, linolenic, olein)). Essentiale medications possess the membranotropic properties, metabolic and hepatoprotective action; regulates lipid and carbohydrate metabolism. Essential phospholipids increase functional status of the liver.
While the disturbance of the liver metabolism essential phospholipids ensure the entering the high energy phospholipids, which are ideally combined with the endogenous phospholipids. Under the Essentialle phospholipids influence clinical and biochemical liver indexes are improved.
Combination of Essentiale with cordiamin (nikethamide) and vitamin E (50 mg/kg for 35 days) considerably activates the mono-oxigenase, glucoro- and glutathione transferase systems of the liver: and as a result the free-radical processes became less intense [1].
The spectrum of essential phospholipids' activity in chronic degenerative liver diseases can be described in the following properties:
- recovery and maintaining the consistency of the hepatocytes;
- activation of the phospholipid-depending ferments;
- improvement in the lipids metabolism caused by accelerated synthesis of lipoproteins in the liver;
- activation of synthesis RNA and as a result the normalization of the proteins metabolism;
- increased synthesis of glycogen in the liver;
- improvement in the detoxification function of the liver;
- the conversion of neutral fats and cholesterol into the easily metabolizing forms;
- decreased the fatty infiltration of the hepatocytes.
Common use
Essentiale is used to treat the following diseases:
- Hepatitis(acute and chronic), toxic hepatitis, medicinal and alcoholic hepatitis, poisonings. Hepatic steatosis of different aetiology(in 53.6 % of patients the effect of six-month treatment with Essentiale forte was very good (improvement of all investigated parameters) [2]
diabetes(the data suggests that Essentiale protects and improves liver function in diabetic subjects with non alcoholic fatty liver[3] [3]) and chronic infections);
- Disturbance in liver function in somatic diseases;
- Hepatic cirrhosis;
- Necrosis of the liver cells, liver failure, liver coma;
- Pre- and Post- surgical treatment, especially in hepatobiliary area;
- Hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia;
- Diseases of the cardiovascular system: coronary heart disease, stable stenocardia [4], post-infarction condition, disturbance of the cerebral and peripheral circulation, Hypertension, thrombembolia prophylaxis, atherosclerosis, diabetic angiopathy, thrombembolia prophylaxis and fat embolism(solution for injection);
- Digestive system diseases (chronic pancreatitis, gastric and duodenum ulcer;
- Toxicosis of pregnancy(edema, proteinuria и and blood pressure disorders);
- Radiation sickness (radiation syndrome);
- Psoriasis, atomic dermatitis, eczema;
- Pyelonephritis [5]
- Prophylaxis of micromegaly.
Availability
Essentiale medications are manufactured under 4 trade names:
ESSENTIALE- solution for intravenous injections in vials 5 ml. Essentiale contains essential phospholipids(EPL substance) 250 mg, Pyridoxine chidrochloride 2,5 mg (Vitamin B6), Cyanocobolamine 0,1 mg (Vitamin B12), Sodium Pantothenate 1.5 mg, Nicotinamide 25 mg
ESSENTIALE FORTE N- Capsules N30 or N100. One capsule contains essential phospholipids (EPL substance) 300 mg.
ESSENTIALE N. -solution for intravenous injection in vials 5 ml. Essentale N contains essential phospholipids(EPL substance) 250 mg.
ESSENTIALE FORTE – capsules N50. Essentiale forte contains essential phospholipids(EPL substance) 300 mg, Thiamine mono nitrate(Vitamin B1)6 mg, Riboflavine(Vitamiin B2) 6 mg, Pyridoxine chidrochloride 6 mg(Vitamin B6), Cyanocobolamine 0.06 mg (Vitamin B12), Nicotinamide 30 mg, Tocopherole acetate 6 mg(Vitamin E).
Contradiction and cautions
Do not use Essentiale in hypersensitivity or allergy to any ingredients of the preparation. The application of Essentiale in newborn children is not safe. During pregnancy women are recommended to consult their health care provider prior to taking Essentiale.
Side effects
In very rare cases it can cause :abdominal pain, nausea, diarrhea and allergic reaction(skin rash).
Recommendation for storage
Capsules should be stored at temperature not more than 20°C. Vials should be stored at 2° - 8°C
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
- ↑ IV Zverinskiĭ, VE Karpovich, MI Bushma, LF Legon'kova, NG Mel'nichenko, LI Nechiporenko, VS Nikitin (1998 Jan-Feb). "The action of Essentiale and its combination with cordiamine and vitamin E". Eksp Klin Farmakol. (61(1):33-6): 212–214. Check date values in:
|date=
(help) - ↑ "The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings--preliminary study" (133(12):366-9). Interní klińika, Institutu postgraduálního vzdélávání ve zdravotnictví, Praha. 1994 Jun. Check date values in:
|date=
(help); - ↑ Poongothai, K Karkuzhali, G Siva Prakash, T Sangeetha, G Saravanan, R Deepa, Sharadha Gopalakrishnan, V Mohan. S Poongothai. Int J Diab Dev Ctries (2005). "EFFECT OF ESSENTIALE IN DIABETIC SUBJECTS WITH NON - ALCOHOLIC FATTY LIVER".
- ↑ "The effect of laser therapy and its combination with essentiale on the course of stable stenocardia". Lik Sprava (0) 0: 72-4.
- ↑ AA Ovchinnikov, VE Tsvettsikh, BA Berdichevskiĭ, VN Lykov, VR Suktanbaev, AV Murychev (1996 Jul-Aug). "Essential phospholipids in the treatment of chronic pyelonephritis". Urol Nefrol (Mosk). Check date values in:
|date=
(help)
- Pages with script errors
- Pages with broken file links
- Orphaned articles from March 2010
- Articles with invalid date parameter in template
- All orphaned articles
- Articles which use infobox templates with no data rows
- Infobox drug articles without a structure image
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs
- 2Fix
- CS1 errors: dates
- CS1 maint: Multiple names: authors list
- Pages using citations with accessdate and no URL